Live Breaking News & Updates on சனோஃபி அவென்ட்டிஸ் ஐயர்ல்யாஂட்

Stay updated with breaking news from சனோஃபி அவென்ட்டிஸ் ஐயர்ல்யாஂட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

China Hydroxychloroquine Markets, 2016-2020 & 2021-2025 - Impact of COVID-19 on the Market


Share this article
Share this article
ResearchAndMarkets.com s offering.
The sales of hydroxychloroquine in the Chinese market have been rising steadily, from CNY 258 million in 2016 to CNY 343 million in 2020, with a CAGR of 7.34% from 2016 to 2020. In 2020, China s sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.
Hydroxychloroquine is commonly used to prevent and treat malaria. The pharmacokinetics of hydroxychloroquine is similar to that of chloroquine. It can be rapidly absorbed in the gastrointestinal tract and excreted in the kidneys. Hydroxychloroquine is also used in the treatment of rheumatoid arthritis, lupus erythematosus, and delayed skin lesions purpura.
The market demand for hydroxychloroquine in China is relatively large. There are two companies approved for manufacturing hydroxychloroquine, namely Shanghai Zhongxi Pharmaceutical Co., Ltd. and Sanofi-aventis Ireland Ltd. Shanghai Zhongxi Pharmaceutical Co., ....

Hydroxychloroquine Fenle , Laura Wood , Hydroxychloroquine Plaquenil , National Health Commission Of China , Office Hours Call , Shanghai Zhongxi Pharmaceutical Co Ltd , World Health Organization , Drug Administration , Development Of Hydroxychloroquine , E St Office Hours Call , Shanghai Municipal Health Commission , Development Of China Hydroxychloroquine Market , Sanofi Aventis Ireland Ltd , Hydroxychloroquine Market , Sanofi Aventis Ireland , Shanghai Zhongxi Pharmaceutical , Emergency Use Authorization , Hydroxychloroquine Sulfate , Treatment Plan , Trial Eighth Edition , National Health Commission , Topics Covered , Dosage Form , Major Hydroxychloroquine Manufacturers , Market Share , Major Hydroxychloroquine ,

Investegate |Uniphar PLC Announcements | Uniphar PLC: Directorate Changes


 
Dublin, London | 27 January 2021:
Uniphar plc (the Company or Uniphar ) is pleased to announce the appointment of James ( Jim ) Gaul and Elizabeth ( Liz ) Hoctor to its Board as independent non-executive Directors with immediate effect.
Jim Gaul
Jim Gaul is an experienced executive and non-executive director with a strong track record in financial management in multinational pharmaceutical and healthcare sector companies. He is a former CFO of Sanofi Ireland, with thirty years experience in companies across the healthcare value chain, from early stage/R&D pharma to patient-facing hospital services. Jim is also former CFO of Mount Carmel Private Hospital. Jim is a Certified Public Accountant with experience in financial management, successful strategic business modelling and achieving business growth. He has an interest and experience in the achievement of success through people and is an experienced change manager and mentor ....

United Kingdom , City Of , Maurice Pratt , Ben Maddison , Matt Blawat , Orla Cowzer , Barry Murphy , Elizabeth Liz Hoctor , Iarla Mongey , Padraic Staunton , James Jim Gaul , Fergal Meegan , Thomas Debrosse , Marie Mcconn , Jeff Berkowitz , Brian Oshaughnessy , Jim Gaul , Jonathan Hardy , Liz Hoctor , Carraig Insurance Ltd , Sanofi Aventis Ireland , International Healthcare Systems , Hoechst Marion Roussel Ireland , Clinical The Group , Transition Therapeutics Ireland , Product Access The Group ,